Core Insights - PROCEPT BioRobotics is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at two investor conferences in March 2026, indicating active engagement with the investment community [1][2] Company Overview - PROCEPT BioRobotics aims to revolutionize the treatment of Benign Prostatic Hyperplasia (BPH) globally by partnering with urologists [3] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting a significant market opportunity for the company [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference [2] - A live webcast of each event will be available on the company's website, with recordings archived for at least 90 days [2] - Specific event details include a fireside chat on March 2 at 11:40 am ET in Boston, MA, and another on March 10 at 8 am ET in Miami, FL [4]

Company Overview - PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care in urology by developing transformative solutions [3] - The company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), independent of prostate size and surgeon experience [3] Financial Reporting - The company will report its financial results for the third quarter of 2025 after market close on November 4, 2025 [1] - A conference call will be hosted by the company's management at 4:30 p.m. Eastern Time on the same day [1] Clinical Evidence - PROCEPT BioRobotics has developed a significant body of clinical evidence with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [3]